Clearance of Recombinant Tissue Factor Pathway Inhibitor (TFPI) in Rabbits

Summary

The pharmacokinetics of recombinant tissue factor pathway inhibitor (TFPI) after an intravenous bolus injection was studied in rabbits. Clearance of TFPI was followed by measurement of the radioactivity of the ¹²⁵I-labelled compound in the whole plasma or the trichloroacetic acid precipitate and by quantitation of the functional TFPI activity of the unlabelled compound using a tissue factor-induced coagulation assay. When iodinated TFPI was used, the ratios of the trichloroacetic acid precipitable counts vs. that of the whole plasma was about 1 in the first 10 min after TFPI injection, but this ratio gradually decreased to less than 0.5 after 2 h. This result suggested that the iodinated TFPI in the plasma was partially degraded after prolonged circulation in the animal. When unlabelled TFPI was used, the clearance of TFPI activity from the plasma exhibited bi-exponential elimination kinetics with a rapid alpha phase half-life $$(t _1/2α) of 2.3 min, and a terminal beta phase half-life $$(t _1/2β) of 79 min. The plasma clearance was 4.2 ml kg^–1 min^–1. The tissue distribution of intravenously administered ¹²⁵I-TFPI in the rabbit was studied using whole-body autoradiography. At 3 min after dosing, significant levels of TFPI were apparent in the liver, kidney, and other highly blood perfused tissues. Signficant levels of ¹²⁵I-TFPI-derived radioactivity were also apparent in the liver and kidney at 30 min after intravenous administration. The localization within the liver demonstrated a mottled appearance, suggesting regions of higher uptake within the liver. In the kidney, the outer cortex consistently revealed the highest activity.

• References

• 1 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8
• 2 Rao LVM, Rapaport SI. Studies on the mechanism of inactivation of the extrinsic pathway of coagulation. Blood 1987; 69: 645-651
• 3 Broze Jr GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor X_a: insight into its possible mechanism of action. Blood 1988; 71: 335-343
• 4 Broze Jr GJ, Miletich JP. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma. Proc Natl Acad Sci USA 1987; 84: 1886-1890
• 5 Wun T-C, Huang MD, Kretzmer KK, Palmier MO, Day KC, Bulock JW, Fok KF, Broze Jr GJ. Immunoaffinity purification and characterization of lipoprotein-associated coagulation inhibitors from HepG2 hepatoma, Chang liver, and SK hepatoma cells. J Biol Chem 1990; 265: 16096-101
• 6 Novotny WF, Girard TJ, Miletich JP, Broze Jr GJ. Purification and characterization of lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-18837
• 7 Wun T-C, Kretzmer KK, Girard TJ, Miletich JP, Broze Jr GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-6004
• 8 Day KC, Hoffman LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze Jr GJ. Warren TG, Wun T-C. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in rabbit. Blood 1990; 76: 1538-1545
• 9 Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen PM, Moeller KB, Meidahl-Pederson J, Beck TC, Norris K, Hedner U, Kisiel W. Recombinant human extrinsic pathway inhibitor: production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem 1990; 28: 16786-16793
• 10 Wun T-C, Kretzmer KK, Palmier MO, Day KC, Huang MD, Welsch DJ, Lewis C, Wolfe RA, Zobel JF, Lange GW, Frazier RB, Bild GS, Peel MA, Shell RE, Horn NA, Junger KD, Foy BA, Gustafson ME, Novotny WF, Broze Jr J, Pyla YE, Hippenmeyer PJ, Warren TG. Comparison of recombinant tissue factor pathway inhibitors expressed in human SK hepatoma, mouse C127, baby hamster kidney, and Chinese hamster ovary cells. Thromb Haemostas 1992; 68: 54-59
• 11 Haskel EJ, Torr SR, Day KC, Palmier MO, Wun T-C, Sobel BE, Abendschein DR. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991; 84: 821-827
• 12 Markwell MAK. A new solid-state reagent to iodinate proteins. Anal Biochem 1982; 125: 427-432
• 13 Gibaldi M, Perrier D. Pharmacokinetics, second edition. Drug and the Pharmaceutical Sciences Series, Vol. 15. Marcel Dekker, Inc.; New York: 1982
• 14 Tuey DB. Toxicokinetics. Introduction to Biochemical Toxicology. Elsevier; New York: 1980: 40-66
• 15 Wilson AGE, Hall LJ. Application of whole-body autoradiography in toxicology. Toxicol Methods 1991; 3: 147-160
• 16 Hotchkiss AS, Refino CJ, Leonard CK, O’Connor JV, Crowley C, McCabe J, Tate K, Nakamura G, Powers D, Levinson A, Mohler M, Spellman MW. The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thromb Haemostas 1988; 60: 255-261
• 17 Einarsson M, Haggroth L, Mattson C. Elimination of carbohydrate-modified tissue plasminogen activator in rabbits. Thromb Haemostas 1989; 62: 1088-1093